Tempest Therapeutics, Inc. — Director's Dealing 2017

Jun 24, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2017-06-21

Reporting Person: Dipp Michelle (Director, Executive Chair)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-06-21	Stock Option (right to buy)	$1.46	A	175000	Acquired	2027-06-21	Common Stock (175000)	Direct

Footnotes

F1: (1) 12.5% of the shares underlying the option shall vest on September 21, 2017 and 12.5% of the shares underlying the option shall vest at the end of each successive three-month period thereafter until June 21, 2019.